MindMed Posts Positive Phase II Results for LSD-Based Treatment for Anxiety

New York-based biotech MindMed on Thursday reported topline results from a Phase IIb trial of its LSD-based candidate MM-120 (lysergide d-tartrate), which met the study’s primary endpoint in patients with generalized anxiety disorder.